Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Loibl S, Tang G, Nekljudova V, Rastogi P, Rachakonda S, Reinisch M, Acosta J, Schneeweiss A, Hilton C, Seiler S, Bhargava R, Karn T, Cortazar P, Moreno F, Andersen J, Christensen S, Klare P, Murali S, Morales S, Huober J, Boileau JF, Rodríguez-Lescure Á, Boudreau D, Polewski PJ, Teply-Szymanski J, Mouta J, Mamounas EP, Denkert C, Wolmark N, Geyer CE Jr

Open source

DOI: 10.1038/s41591-026-04565-6
Published: 2026 Oct
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04565-6,
  title = {Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.},
  author = {Loibl S and Tang G and Nekljudova V and Rastogi P and Rachakonda S and Reinisch M and Acosta J and Schneeweiss A and Hilton C and Seiler S and Bhargava R and Karn T and Cortazar P and Moreno F and Andersen J and Christensen S and Klare P and Murali S and Morales S and Huober J and Boileau JF and Rodríguez-Lescure Á and Boudreau D and Polewski PJ and Teply-Szymanski J and Mouta J and Mamounas EP and Denkert C and Wolmark N and Geyer CE Jr},
  year = {2026},
  journal = {Nature medicine},
  doi = {10.1038/s41591-026-04565-6},
  url = {https://doi.org/10.1038/s41591-026-04565-6}
}

RIS

TY  - JOUR
TI  - Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.
AU  - Loibl S
AU  - Tang G
AU  - Nekljudova V
AU  - Rastogi P
AU  - Rachakonda S
AU  - Reinisch M
AU  - Acosta J
AU  - Schneeweiss A
AU  - Hilton C
AU  - Seiler S
AU  - Bhargava R
AU  - Karn T
AU  - Cortazar P
AU  - Moreno F
AU  - Andersen J
AU  - Christensen S
AU  - Klare P
AU  - Murali S
AU  - Morales S
AU  - Huober J
AU  - Boileau JF
AU  - Rodríguez-Lescure Á
AU  - Boudreau D
AU  - Polewski PJ
AU  - Teply-Szymanski J
AU  - Mouta J
AU  - Mamounas EP
AU  - Denkert C
AU  - Wolmark N
AU  - Geyer CE Jr
PY  - 2026
JO  - Nature medicine
DO  - 10.1038/s41591-026-04565-6
UR  - https://doi.org/10.1038/s41591-026-04565-6
ER  -

APA

S, L., G, T., V, N., P, R., S, R., M, R., J, A., A, S., C, H., S, S., R, B., T, K., P, C., F, M., J, A., S, C., P, K., S, M., S, M., J, H., JF, B., Á, R., D, B., PJ, P., J, T., J, M., EP, M., C, D., N, W., & Jr, G. C. (2026). Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.. Nature medicine. https://doi.org/10.1038/s41591-026-04565-6

Source records

pubmed · retrieved 2026-11-11T01:14:41.866Z